Next Article in Journal
Heart–Lung–Muscle Anti-SAE Syndrome: An Atypical Severe Combination
Previous Article in Journal
Novel Immune Features of the Systemic Inflammation Associated with Primary Hypercholesterolemia: Changes in Cytokine/Chemokine Profile, Increased Platelet and Leukocyte Activation
Open AccessEditor’s ChoiceArticle

Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR

University of California San Francisco, Department of Surgery, San Francisco, CA 94143, USA
Natera, Inc., San Carlos, CA 94070, USA
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
At time of study.
J. Clin. Med. 2019, 8(1), 19;
Received: 15 November 2018 / Revised: 15 December 2018 / Accepted: 17 December 2018 / Published: 23 December 2018
(This article belongs to the Section Nephrology & Urology)
Standard noninvasive methods for detecting renal allograft rejection and injury have poor sensitivity and specificity. Plasma donor-derived cell-free DNA (dd-cfDNA) has been reported to accurately detect allograft rejection and injury in transplant recipients and shown to discriminate rejection from stable organ function in kidney transplant recipients. This study used a novel single nucleotide polymorphism (SNP)-based massively multiplexed PCR (mmPCR) methodology to measure dd-cfDNA in various types of renal transplant recipients for the detection of allograft rejection/injury without prior knowledge of donor genotypes. A total of 300 plasma samples (217 biopsy-matched: 38 with active rejection (AR), 72 borderline rejection (BL), 82 with stable allografts (STA), and 25 with other injury (OI)) were collected from 193 unique renal transplant patients; dd- cfDNA was processed by mmPCR targeting 13,392 SNPs. Median dd-cfDNA was significantly higher in samples with biopsy-proven AR (2.3%) versus BL (0.6%), OI (0.7%), and STA (0.4%) (p < 0.0001 all comparisons). The SNP-based dd-cfDNA assay discriminated active from non-rejection status with an area under the curve (AUC) of 0.87, 88.7% sensitivity (95% CI, 77.7–99.8%) and 72.6% specificity (95% CI, 65.4–79.8%) at a prespecified cutoff (>1% dd-cfDNA). Of 13 patients with AR findings at a routine protocol biopsy six-months post transplantation, 12 (92%) were detected positive by dd-cfDNA. This SNP-based dd-cfDNA assay detected allograft rejection with superior performance compared with the current standard of care. These data support the feasibility of using this assay to detect disease prior to renal failure and optimize patient management in the case of allograft injury. View Full-Text
Keywords: cfDNA; kidney transplantation; rejection cfDNA; kidney transplantation; rejection
Show Figures

Figure 1

MDPI and ACS Style

Sigdel, T.K.; Archila, F.A.; Constantin, T.; Prins, S.A.; Liberto, J.; Damm, I.; Towfighi, P.; Navarro, S.; Kirkizlar, E.; Demko, Z.P.; Ryan, A.; Sigurjonsson, S.; Sarwal, R.D.; Hseish, S.-C.; Chan-On, C.; Zimmermann, B.; Billings, P.R.; Moshkevich, S.; Sarwal, M.M. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR. J. Clin. Med. 2019, 8, 19.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop